Testing a new drug combo for T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing two drugs together: GW5282 and golidocitinib. It aims to see if this combination can help people with a type of T-cell lymphoma called PTCL. The trial is for patients who have already received other treatments or where standard options are limited.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with a type of T-cell lymphoma called peripheral T-cell lymphoma (PTCL)
- Your cancer is measurable (can be seen on scans)
- You are in generally good health aside from your lymphoma
- You are not pregnant or breastfeeding and will use birth control during the trial
- You have not had another cancer in the past (with some exceptions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new drug combined with chemotherapy for patients whose T-cell lymphoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink tumors and improve outcomes.
This trial tests a new oral medication called golidocitinib for people who have just been diagnosed with a specific type of T-cell lymphoma and have not had any prior treatment. The goal is to see if this JAK1 inhibitor can help control the disease.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hear when a new T-cell Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.